Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
Clinical trial NCT04209205 · COMPLETED
Trial details
- NCT number
- NCT04209205
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-29
- Primary completion
- 2022-05-17
- Enrollment
- 381
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.